Browse NLRP2

Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF13516 Leucine Rich repeat
PF02758 PAAD/DAPIN/Pyrin domain
Function

Suppresses TNF- and CD40-induced NFKB1 activity at the level of the IKK complex, by inhibiting NFKBIA degradation induced by TNF. When associated with PYCARD, activates CASP1, leading to the secretion of mature proinflammatory cytokine IL1B. May be a component of the inflammasome, a protein complex which also includes PYCARD, CARD8 and CASP1 and whose function would be the activation of proinflammatory caspases.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0009306 protein secretion
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0032611 interleukin-1 beta production
GO:0032612 interleukin-1 production
GO:0032651 regulation of interleukin-1 beta production
GO:0032652 regulation of interleukin-1 production
GO:0032731 positive regulation of interleukin-1 beta production
GO:0032732 positive regulation of interleukin-1 production
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0045862 positive regulation of proteolysis
GO:0050663 cytokine secretion
GO:0050701 interleukin-1 secretion
GO:0050702 interleukin-1 beta secretion
GO:0050704 regulation of interleukin-1 secretion
GO:0050706 regulation of interleukin-1 beta secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050716 positive regulation of interleukin-1 secretion
GO:0050718 positive regulation of interleukin-1 beta secretion
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:1903532 positive regulation of secretion by cell
GO:1904951 positive regulation of establishment of protein localization
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0032090 Pyrin domain binding
Cellular Component GO:0000781 chromosome, telomeric region
GO:0000784 nuclear chromosome, telomeric region
GO:0044454 nuclear chromosome part
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NLRP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NLRP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NLRP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4570.327
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2430.75
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6240.336
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7330.415
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3240.546
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0110.997
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.0260.216
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5990.176
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4120.743
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0080.102
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2090.151
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.9010.0466
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NLRP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.812.32.50.744
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.815.3-0.51
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171917.61.41
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.127.3-4.21
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLRP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLRP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLRP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLRP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NLRP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NLRP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNLRP2
NameNLR family, pyrin domain containing 2
Aliases FLJ20510; PYPAF2; PAN1; CLR19.9; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin do ......
Chromosomal Location19q13.42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NLRP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.